Viridian Therapeutics, Inc. (VRDN)
Last updated: 2026-10-21 20:13:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Viridian Therapeutics, Inc. (VRDN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23.01, with a market capitalization of $2.36B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.18 to $34.29. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.36B | |
$22.50 | |
$39.00 | |
$9.47 | |
$22.43 | |
1.55M | |
1.79M | |
-- | |
$34.29 | |
$13.18 | |
-- | |
-- |
Viridian Therapeutics, Inc. (VRDN) After-Hours Stock Price
Viridian Therapeutics, Inc. (VRDN) is trading at $22.84 in after-hours trading as of 2026-10-21 19:56:38, up 1.81% ($0.41) from the regular-session close of $22.43.
After-hours trading shows how investors are pricing VRDN after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Viridian Therapeutics, Inc. (VRDN) 7-Day Stock Price Change
Over the past seven days, Viridian Therapeutics, Inc. (VRDN) moved from $18.30 to $23.01, representing a gain of 25.72% ($4.71).
The stock traded between $17.96 and $23.28 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.43 million shares, up versus the previous seven-day period, indicating higher trading activity.
VRDN 52-Week Price Position
Position in Range: 46.6%
VRDN is currently trading at $23.01, placing it 46.6% of the way from its 52-week low of $13.18 to its 52-week high of $34.29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Viridian Therapeutics, Inc. (VRDN)?
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 252 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Viridian Therapeutics, Inc. (VRDN) Stock on MEXC
Eligible investors can buy real shares of Viridian Therapeutics, Inc. (VRDN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Viridian Therapeutics, Inc. (VRDN) stock price today?
2.Is VRDN stock going up or down today?
3.What is VRDN pre-market price?
4.What is VRDN after-hours price?
5.Is VRDN stock trading now?
6.Where does VRDN sit relative to its 52-week high and low?
7.What sector is Viridian Therapeutics, Inc. in?
8.What is Viridian Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is VRDN valued in terms of P/E ratio and EPS?
10.Does Viridian Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
VRDN Stock Calculator
Estimate the value between VRDN shares and USD.
VRDN Shares to USD
1.00 VRDN shares = 23.007 USD
Calculations are estimates based on the latest available price and are for reference only.




